Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Severe Pulmonary Toxicity in a Patient Treated With Gemcitabine

Rosado, Manuel F., M.D.; Kett, Daniel H., M.D.; Schein, Roland M.H., M.D.; Baraona, Francisco J., M.D.; Sridhar, Kasi S., M.D.

American Journal of Clinical Oncology: February 2002 - Volume 25 - Issue 1 - p 31-33
Articles
Buy

Gemcitabine is a pyrimidine analog of deoxycytidine with activity against nonhematologic and hematologic malignancies. Its pulmonary toxicity is usually mild and self-limiting. We describe a male patient with lung cancer in whom severe dyspnea and interstitial infiltrates developed after the administration of gemcitabine.

Departments of Medicine (M.F.R.) and Critical Care (D.H.K., R.M.H.S.), and Pulmonary Department (F.J.B.), Jackson Memorial Hospital, University of Miami School of Medicine, and Division of Hematology-Oncology (K.S.S.), University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, U.S.A.

Address correspondence and reprint requests to Dr. Manuel F. Rosado, Department of Medicine, Jackson Memorial Hospital, 1611 NW 12th Avenue, Miami, FL 33136-1094, U.S.A.

© 2002 Lippincott Williams & Wilkins, Inc.